低氧诱导因子-1α在糖尿病肾病中作用机制的研究进展

doi:10.16352/j.issn.1001-6325.2024.01.0114

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (1): 114-118.doi: 10.16352/j.issn.1001-6325.2024.01.0114

低氧诱导因子-1α在糖尿病肾病中作用机制的研究进展

张雅慧, 白琼^*

北京大学第三医院肾内科,北京 100191

收稿日期:2023-03-16 修回日期:2023-07-31 出版日期:2024-01-05 发布日期:2023-12-25
通讯作者: ^*:baiqiong@bjmu.edu.cn
基金资助:
北京大学第三医院临床重点项目(BYSYZD2021036);北京大学第三医院人才孵育基金(BYSYFY2021025)

Research progress of hypoxia inducible factor 1α in the mechanism of diabetic kidney disease

ZHANG Yahui, BAI Qiong^*

Department of Nephrology, Peking University Third Hospital, Beijing 100191, China

Received:2023-03-16 Revised:2023-07-31 Online:2024-01-05 Published:2023-12-25
Contact: ^*:baiqiong@bjmu.edu.cn

摘要/Abstract

摘要： 低氧诱导因子-1α (HIF-1α) 是一种核转录因子。在高糖低氧条件下,HIF-1α表达增加,诱导其下游靶基因VEGF、HO-1和BNIP3的表达,通过影响血管生成、细胞外基质沉积、铁代谢及线粒体自噬参与糖尿病肾病(DKD)的发生发展。此外,HIF-1α通过促进细胞因子的产生,参与DKD炎性反应并导致肾脏纤维化。

关键词: 低氧诱导因子-1α, 糖尿病肾病, 发病机制

Abstract: Hypoxia-inducible factor-1α (HIF-1α) is a nuclear transcription factor. Under high glucose and hypoxia conditions, the expression of HIF-1α is elevated, result in the increased expression of its downstream target genes VEGF, HO-1 and BNIP3, which affect angiogenesis, extra cellular matrix deposition, iron metabolism, and mitophagy, participating in the occurrence and development of diabetic kidney disease (DKD). In addition, HIF-1α promotes inflammation and renal fibrosis by affecting the production of cytokines in DKD.

Key words: hypoxia inducible factor 1α, diabetic kidney disease, pathogenesis

中图分类号:

R587.1

张雅慧, 白琼. 低氧诱导因子-1α在糖尿病肾病中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(1): 114-118.

ZHANG Yahui, BAI Qiong. Research progress of hypoxia inducible factor 1α in the mechanism of diabetic kidney disease[J]. Basic & Clinical Medicine, 2024, 44(1): 114-118.

参考文献 29

[1]	Duan JY, Duan GC, Wang CJ, et al. Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in a central Chinese urban population: a cross-sectional survey[J]. BMC Nephrol,2020,21:115. doi: 10.1186/s12882-020-01761-5.
[2]	Tang G, Li S, Zhang C, et al. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management[J]. Acta Pharm Sin B,2021,11:2749-2767. doi: 10.1016/j.apsb.2020.12.020.
[3]	Catrina SB, Zheng X. Hypoxia and hypoxia-inducible factors in diabetes and its complications[J]. Diabetologia,2021,64:709-716. doi: 10.1007/s00125-021-05380-z.
[4]	Yamazaki T, Mimura I, Tanaka T, et al. Treatment of diabetic kidney disease: current and future[J]. Diabetes Metab J,2021,45:11-26. doi: 10.4093/dmj.2020.0217.
[5]	Feng X, Wang S, Sun Z, et al. Ferroptosis enhanced diabetic renal tubular injury via HIF-1α/HO-1 pathway in db/db mice[J]. Front Endocrinol,2021,12. doi: 10.3389/fendo.2021.626390.
[6]	Mei S, Li L, Zhou X, et al. Susceptibility of renal fibrosis in diabetes: role of hypoxia inducible factor-1[J]. FASEB J,2022,36:e22477. doi: 10.1096/fj.202200845R.
[7]	Cai A, Chatziantoniou C, Calmont A. Vascular permeability: regulation pathways and role in kidney dseases[J]. Nephron,2021,145:297-310. doi: 10.1159/000514314.
[8]	Lin CJ, Lan YM, Ou MQ, et al. Expression of miR-217 and HIF-1α/VEGF pathway in patients with diabetic foot ulcer and its effect on angiogenesis of diabetic foot ulcer rats[J]. J Endocrinol Invest,2019,42:1307-1317. doi: 10.1007/s40618-019-01053-2.
[9]	Ando A, Hashimoto N, Sakamoto K, et al. Repressive role of stabilized hypoxia inducible factor 1α expression on transforming growth factor β-induced extracellular matrix production in lung cancer cells[J]. Cancer Sci,2019,110:1959-1973. doi: 10.1111/cas.14027.
[10]	Dou L, Jourde-Chiche N. Endothelial toxicity of high glucose and its by-products in diabetic kidney disease[J]. Toxins (Basel),2019,11. doi: 10.3390/toxins11100578.
[11]	Garcia-Pastor C, Benito-Martinez S, Moreno-Manzano V, et al. Mechanism and consequences of the impaired Hif-1alpha response to hypoxia in human proximal tubular HK-2 cells exposed to high glucose[J]. Sci Rep,2019,9:15868. doi: 10.1038/s41598-019-52310-6.
[12]	Dunn LL, Kong SMY, Tumanov S, et al. Hmox1(heme oxygenase-1) protects against ischemia-mediated injury via stabilization of HIF-1alpha (hypoxia-inducible factor-1alpha)[J]. Arterioscler Thromb Vasc Biol,2021,41:317-330. doi: 10.1161/ATVBAHA.120.315393.
[13]	Chaudhary K, Chilakala A, Ananth S, et al. Renal iron accelerates the progression of diabetic nephropathy in the HFE gene knockout mouse model of iron overload[J]. Am J Physiol Renal Physiol,2019,317:F512-f517. doi: 10.1152/ajprenal.00184.2019.
[14]	Wang Y, Bi R, Quan F, et al. Ferroptosis involves in renal tubular cell death in diabetic nephropathy[J]. Eur J Pharmacol,2020,888:173574. doi: 10.1016/j.ejphar.2020.173574.
[15]	Jiang N, Zhao H, Han Y, et al. HIF-1α ameliorates tubular injury in diabetic nephropathy via HO-1-mediated control of mitochondrial dynamics[J]. Cell Prolif,2020,53. doi: 10.1111/cpr.12909.
[16]	Zhang X, Feng J, Li X, et al. Mitophagy in diabetic kidney disease[J]. Front Cell Dev Biol,2021,9:778011. doi: 10.3389/fcell.2021.778011.
[17]	Chen K, Dai H, Yuan J, et al. Optineurin-mediated mitophagy protects renal tubular epithelial cells against accelerated senescence in diabetic nephropathy[J]. Cell Death Dis,2018,9:105. doi: 10.1038/s41419-017-0127-z.
[18]	张刘杰, 李静, 吴博. HIF-1介导的自噬在心脏疾病中的研究进展[J]. 基础医学与临床,2021,41:1186-1189. doi: 10.3969/j.issn.1001-6325.2021.08.019.
[19]	Li W, Xiang Z, Xing Y, et al. Mitochondria bridge HIF signaling and ferroptosis blockage in acute kidney injury[J]. Cell Death Dis,2022,13:308. doi: 10.1038/s41419-022-04770-4.
[20]	Li C, Zhou J, Liu Z, et al. FSH prevents porcine granulosa cells from hypoxia-induced apoptosis via activating mitophagy through the HIF-1α-PINK1-Parkin pathway[J]. Faseb j,2020,34:3631-3645. doi: 10.1096/fj.201901808RRR.
[21]	Zheng Y, Huang C, Lu L, et al. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib[J]. J Hematol Oncol,2021,14:16. doi: 10.1186/s13045-020-01029-3.
[22]	Madhu V, Boneski PK, Silagi E, et al. Hypoxic regula-tion of mitochondrial metabolism and mitophagy in nucleus pulposus cells is dependent on HIF-1alpha-BNIP3 axis[J]. J Bone Miner Res,2020,35:1504-1524. doi: 10.1002/jbmr.4019.
[23]	Fu ZJ, Wang ZY, Xu L, et al. HIF-1alpha-BNIP3-mediated mitophagy in tubular cells protects against renal ischemia/reperfusion injury [J]. Redox Biol,2020,36:101671. doi: 10.1016/j.redox.2020.101671.
[24]	Sulkshane P, Ram J, Thakur A, et al. Ubiquitination and receptor-mediated mitophagy converge to eliminate oxidation-damaged mitochondria during hypoxia[J]. Redox Biol,2021,45:102047. doi: 10.1016/j.redox.2021.102047.
[25]	Tang SCW, Yiu WH. Innate immunity in diabetic kidney disease[J]. Nat Rev Nephrol,2020,16:206-222. doi: 10.1038/s41581-019-0234-4.
[26]	Levin A, Reznichenko A, Witasp A, et al. Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium[J]. Nephrol Dial Transplant,2020,35:2059-2072. doi: 10.1093/ndt/gfaa121.
[27]	Sur S, Nguyen M, Boada P, et al. FcER1: a novel molecule implicated in the progression of human diabetic kidney disease[J]. Front Immunol,2021,12:769972. doi: 10.3389/fimmu.2021.769972.
[28]	Liu C, Yang M, Li L, et al. A glimpse of inflammation and anti-inflammation therapy in diabetic kidney disease[J]. Front Physiol,2022,13:909569. doi: 10.3389/fphys.2022.909569.
[29]	Li ZL, Lv LL, Wang B, et al. The profibrotic effects of MK-8617 on tubulointerstitial fibrosis mediated by the KLF5 regulating pathway[J]. FASEB J,2019,33:12630-12643. doi: 10.1096/fj.201901087RR.

低氧诱导因子-1α在糖尿病肾病中作用机制的研究进展

Research progress of hypoxia inducible factor 1α in the mechanism of diabetic kidney disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	国蓉, 张森, 袁建辉, 李肖珏, 周姝含, 李守军, 陈燕燕. 紫绀型先天性心脏病患儿瘦素及其受体的表达与低氧诱导因子-1α相关[J]. 基础医学与临床, 2024, 44(2): 225-230.
[2]	陈纤纤, 冯烈, 周颖, 董向楠. 糖尿病肾病与其他类型肾病患者肾组织中Smad1蛋白表达的比较[J]. 基础医学与临床, 2023, 43(7): 1097-1103.
[3]	王丽妍, 安菲, 刁宗礼, 黄红东, 刘文虎. 多肽Apelin减轻高糖诱导的肾脏足细胞损伤[J]. 基础医学与临床, 2023, 43(12): 1771-1777.
[4]	蒋琪, 杨柳, 和娇娇, 李维辛. 脂毒性在肌少症发生发展中作用的研究进展[J]. 基础医学与临床, 2023, 43(12): 1886-1890.
[5]	吕文玥, 李金梦, 李含, 刘雷, 王娜. NR4A1在糖尿病肾病发病中作用的研究进展[J]. 基础医学与临床, 2023, 43(10): 1608-1611.
[6]	孙慧, 陈思宇. 微生物相关肿瘤的发病机制及其治疗的研究进展[J]. 基础医学与临床, 2023, 43(1): 178-182.
[7]	林柏柏, 钱风华, 钱义明, 赵雷, 孙旗, 褚梦瑶, 沈梦雯. 脓毒症并发毛细血管渗漏综合征的研究进展[J]. 基础医学与临床, 2022, 42(7): 1144-1147.
[8]	赵肖灵, 何润之, 孙玉姣, 张小冲, 杨林芳, 王瑞, 程芳. 活动期白癜风患者血清γ干扰素含量升高[J]. 基础医学与临床, 2022, 42(7): 1067-1070.
[9]	邓九红, 郑超, 王声遥, 王心怡. 醋酸泼尼松对糖尿病肾病模型大鼠肾功能、肾脏炎性反应及AMPK/SIRT1信号通路的影响[J]. 基础医学与临床, 2022, 42(2): 243-248.
[10]	吴长宝, 郝延磊. STAT3与帕金森病发病机制的研究进展[J]. 基础医学与临床, 2022, 42(12): 1935-1938.
[11]	王行行, 王导新. NETs与急性呼吸窘迫综合征的研究进展[J]. 基础医学与临床, 2021, 41(7): 1047-1051.
[12]	方黄毅, 尤朝国, 庞晨, 章钟鼎, 张哲, 况统帅, 盛汉松. FM19G11体外增敏替莫唑胺对MGMT阳性恶性胶质瘤细胞系的作用机制[J]. 基础医学与临床, 2021, 41(4): 514-520.
[13]	李梦婕, 柯本, 龙脉, 房向东. 线粒体融合蛋白Mfn2在糖尿病肾病中作用的研究进展[J]. 基础医学与临床, 2021, 41(12): 1823-1827.
[14]	孙凤起, 武韧, 常贵全, 李鸿珠. 肾小球系膜细胞增殖在糖尿病肾病肾小球硬化中作用的研究进展[J]. 基础医学与临床, 2021, 41(10): 1510-1513.
[15]	谢飞, 周美兰. 羟基红花黄色素A抑制高糖诱导的小鼠肾足细胞损伤[J]. 基础医学与临床, 2021, 41(1): 27-32.